Fig. 6: Agonistic CD40 treatment improves 4T1 tumor response to RT + CTLA4i.

BALB/c female mice were injected s.c. with 4T1 cells at day 0 in the flank. a Treatment schedule for testing multiple combination therapies (b, c). Dosing and antibody clone name are indicated for each target tested in combination with RT+CTLA4i therapy, (n = 9 biologically independent mice/group except for control n = 5). b Waterfall plots showing tumor volume change between day 11 and day 33 following tumor inoculation. c Response to treatment of each mouse was measured using the 5-category method that classifies responses into complete response (CR), maintained CR (MCR), partial response (PR), stable disease (SD), and progressive disease (PD). CR, complete tumor regression at at least one assessment with regrowth before the end of the experiment; MCR, remained tumor free until the end of the experiment. d Treatment schedule for e and f, (n = 10 biologically independent mice/group except for control n = 5). e Waterfall plots showing the best tumor response (day 31 following tumor inoculation). f Response to treatment combinations assessed using the 5-category method. Mann–Whitney test was applied to log-transformed tumor volume change values. Source data are provided in the Source Data file.